Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Cancer in the crosshairs.

Martindale D.

Sci Am. 2001 Sep;285(3):19-20. No abstract available.

PMID:
11524965
2.

[Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia].

Nielsen JL.

Ugeskr Laeger. 2003 May 12;165(20):2111. Danish. No abstract available.

PMID:
12812107
3.

Imatinib mesylate: a new pill for chronic myelogenous leukemia.

Parmar KK, King RS.

Cancer Pract. 2001 Sep-Oct;9(5):263-5. No abstract available.

PMID:
11879324
4.

STI-571 in chronic myelogenous leukaemia.

Tsao AS, Kantarijian H, Talpaz M.

Br J Haematol. 2002 Oct;119(1):15-24. Review. No abstract available.

PMID:
12358949
5.

Beyond Gleevec--the next generation in CML.

Fricker J.

Eur J Cancer. 2006 Feb;42(3):275. No abstract available.

PMID:
16514710
6.

Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.

Champlin RE, Kantarjian H.

Clin Adv Hematol Oncol. 2003 Jul;1(7):398-400. No abstract available.

PMID:
16258420
7.

Introduction: chronic myelogenous leukemia (CML).

Jabbour E, Kantarjian H.

Semin Hematol. 2007 Jan;44(1 Suppl 1):S1-3. No abstract available.

PMID:
17292735
8.

[Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].

Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2006 Jul;27(7):433-5. Chinese. No abstract available.

PMID:
17147242
9.
10.

Small molecule: large hopes.

Szer J, Lieschke GJ.

Intern Med J. 2001 Sep-Oct;31(7):382-3. No abstract available.

PMID:
11584898
11.

Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.

Jin J, Chen H, Cao L.

Leuk Res. 2009 Jun;33(6):e18-9. doi: 10.1016/j.leukres.2008.10.029. Epub 2008 Dec 23. No abstract available.

PMID:
19108890
12.

Antituberculosis therapy and imatinib for chronic myeloid leukemia.

Sorà F, De Matteis S, Di Mario A, Maiuro G, Laurenti L, Chiusolo P, Ardito F, Leone G, Sica S.

Clin Infect Dis. 2006 Nov 1;43(9):1224. No abstract available.

PMID:
17029152
13.

Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.

Richardson MW, Grewal SS.

Pediatr Blood Cancer. 2008 Jan;50(1):186. No abstract available.

PMID:
17455313
14.
15.

FDA approves Gleevec for pediatric leukemia.

[No authors listed]

FDA Consum. 2003 Jul-Aug;37(4):6. No abstract available.

16.

Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.

Uchiyama M, Ikeda T.

Leuk Res. 2009 Dec;33(12):1723-4. doi: 10.1016/j.leukres.2009.05.011. Epub 2009 Jul 5. No abstract available.

PMID:
19580999
17.

[Imatinib--en epoch-making new drug against chronic myeloid leukemia].

[No authors listed]

Lakartidningen. 2003 Jun 26;100(26-27):2283. Swedish. No abstract available.

PMID:
12872372
18.

[Chronic myeloid leukemia and imatinib mesylate therapy].

Chrobák L.

Vnitr Lek. 2004 Jan;50(1):10-2. Czech. No abstract available.

PMID:
15015223
19.

Quick success for cancer kinase treatment.

[No authors listed]

Nat Med. 2001 Jun;7(6):637. No abstract available.

PMID:
11385473
20.

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

Druker BJ.

Oncogene. 2002 Dec 9;21(56):8541-6. Review. No abstract available.

Supplemental Content

Support Center